Home » Stocks » Jounce Therapeutics

Jounce Therapeutics, Inc. (JNCE)

Stock Price: $6.51 USD -0.17 (-2.54%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 221.69M
Revenue (ttm) 136.89M
Net Income (ttm) 42.76M
Shares Out 34.05M
EPS (ttm) 1.24
PE Ratio 5.25
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 2, 2020
Last Price $6.51
Previous Close $6.68
Change ($) -0.17
Change (%) -2.54%
Day's Open 6.80
Day's Range 6.42 - 6.98
Day's Volume 186,927
52-Week Range 2.79 - 10.00

More Stats

Market Cap 221.69M
Enterprise Value 93.82M
Earnings Date (est) Aug 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 34.05M
Float 17.04M
EPS (basic) 1.31
EPS (diluted) 1.24
FCF / Share -0.92
Dividend n/a
Dividend Yield n/a
Earnings Yield 19.05%
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.45M
Short Ratio 5.90
Short % of Float 8.49%
Beta 2.37
PE Ratio 5.25
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 1.62
PB Ratio 1.41
Revenue 136.89M
Operating Income 39.12M
Net Income 42.76M
Free Cash Flow -31.42M
Net Cash 127.86M
Net Cash / Share 3.75
Gross Margin 89.12%
Operating Margin 28.58%
Profit Margin 31.20%
FCF Margin -22.95%
ROA 12.34%
ROE 34.63%
ROIC 32.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (6)

Buy 2
Overweight 1
Hold 2
Underweight 0
Sell 1

Analyst Consensus: Overweight

Price Target

$9.88*
(51.77% upside)
Low
5.50
Current: 6.51
High
15.00
Target: 9.88
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014
Revenue14865.2071.6437.20--
Revenue Growth126.79%-8.99%92.61%---
Gross Profit14865.2071.6437.20--
Operating Income52.82-31.29-19.22-14.47-30.40-16.21
Net Income56.82-27.38-16.44-13.70-28.53-10.52
Shares Outstanding33.0832.5730.062.101.621.18
Earnings Per Share1.66-0.84-0.57-11.00-23.13-10.93
Operating Cash Flow-30.13-63.61-90.99180-25.74-14.91
Capital Expenditures-0.99-1.36-15.11-2.22-2.20-0.70
Free Cash Flow-31.11-64.97-106177-27.94-15.61
Cash & Equivalents16919023614945.1645.16
Total Debt19.79-----
Net Cash / Debt14919023614945.1645.16
Assets20621429727152.9852.98
Liabilities31.291101301998.128.12
Book Value175104167-69.09-58.76-58.76
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Jounce Therapeutics, Inc.
Country United States
Employees 131
CEO Richard Murray

Stock Information

Ticker Symbol JNCE
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: JNCE
IPO Date January 27, 2017

Description

Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company offers vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors, which is in Phase II clinical trial for the treatment of PD-1/PD-L1 inhibitor patients with non-small cell lung cancer and urothelial cancer. It is also developing JTX-4014, a clinical-stage anti-PD-1 antibody for combination therapy; and JTX-1811, a monoclonal antibody designed to selectively deplete T regulatory cells in the tumor microenvironment that is in the IND-enabling phase. The company's product candidate includes JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.